智通财经网·2026-03-22 23:23Core Insights - The company reported a revenue of RMB 575.168 billion for the year ending December 31, 2025, representing a year-on-year decrease of 1.6% [1] - The profit attributable to equity holders increased by 1.5% to RMB 7.155 billion, with earnings per share at RMB 2.29 and a proposed final dividend of RMB 0.69 per share [1] - The company focused on operational efficiency improvements through cost reduction and lean management, resulting in a decrease in overall expense ratio by 0.25 percentage points [1] Financial Performance - Operating cash flow achieved a net inflow of RMB 14.138 billion, an increase of RMB 2.592 billion compared to the previous year, indicating effective cash flow management [1] - The growth rate of accounts receivable significantly narrowed, reflecting the effectiveness of special governance measures [1] - The debt-to-asset ratio decreased by 2.12 percentage points year-on-year, showcasing improved internal governance efficiency [1] Business Segments - The company aims for high-quality development, focusing on market share expansion and innovation-driven efficiency improvements [2] - The pharmaceutical distribution segment accounted for 72.79% of total revenue, a slight decrease of 0.37 percentage points year-on-year [2] - The medical device distribution segment represented 19.32% of revenue, down by 0.09 percentage points, while the pharmaceutical retail segment increased to 6.42%, up by 0.50 percentage points [2]